Physician profile
Lori N Byrd
NPI 1922021864
$11,713.23
in general payments reported to CMS, 2019-2025
30 companies · $174 in 2025
The $174 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,524 · 2020: $1,288 · 2021: $1,931 · 2022: $3,074 · 2023: $2,391 · 2024: $331 · 2025: $174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,796 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,796.05 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,409.04 | 2019-2024 | Rinvoq, Skyrizi, Humira |
| Novartis Pharmaceuticals Corporation | $1,324.99 | 2019-2025 | |
| Lilly USA, LLC | $1,154.33 | 2019-2024 | Olumiant, Taltz |
| E.R. Squibb & Sons, L.L.C. | $825.35 | 2022-2023 | Sotyktu |
| Janssen Biotech, INC. | $785.23 | 2019-2024 | Tremfya, Stelara, Simponi |
| Amgen INC. | $734.29 | 2019-2023 | Otezla |
| Galderma Laboratories, L.P. | $671.85 | 2019-2023 | Epsolay, Oracea, Aklief |
| Merz North America, INC. | $594.67 | 2019-2021 | |
| Leo Pharma INC. | $510.31 | 2020-2023 | Adbry |
| Genzyme Corporation | $470.86 | 2019-2023 | |
| Pfizer INC. | $350.31 | 2019-2023 | |
| Incyte Corporation | $268.75 | 2021-2022 | |
| Vyne Pharmaceuticals INC. | $229.15 | 2020-2021 | |
| Ucb, INC. | $193.41 | 2019-2023 | Bimzelx, Cimzia |
| Celgene Corporation | $172.25 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.72 | 2022-2023 | Spevigo |
| Dermavant Sciences, INC. | $125.00 | 2022 | |
| Genentech USA, INC. | $109.63 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $108.68 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $92.91 | 2019-2023 | Dupixent |
| Dermira, INC. | $87.07 | 2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $80.33 | 2019-2022 | |
| Medimetriks Pharmaceuticals, INC. | $75.04 | 2020 | |
| Kyowa Kirin, INC. | $74.47 | 2022 | |
| Biofrontera INC. | $36.10 | 2021-2022 | |
| Allergan, INC. | $23.07 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $21.44 | 2019 | |
| Smith+Nephew, INC. | $17.63 | 2020 | |
| Almirall LLC | $14.63 | 2019 | |
| Mayne Pharma Commercial LLC | $13.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Byrd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.